

The effects of HPMC concentration as a new pharmaceutical dosage form on phage release pattern from gels

Meysam Adibi^{1,2}, Ava Soltani Hekmat³, Nazanin Mobasher⁴, Younes Ghasemi^{5,6,7}, Milad Mohkam^{5,6}, Shima Jafari^{1,2}, Mohammad Ali Mobasher^{1,2,*}

¹Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.

²Noncommunicable Diseases Research Center, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.

³Department of Physiology, Fasa University of Medical Sciences, Fasa, Iran.

⁴Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

⁵Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

⁶Pharmaceutical Sciences Research Center, Shiraz University of Medical Science, Shiraz, Iran.

⁷Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Bacterial resistance to various antibiotics has been accelerated in recent years. Bacteriophages (phages) are natural particles that can attack bacteria. Phages can be used selectively for each particular strain. The best way for dealing with superficial infections is topical application of the drug. One of the best ways is the use of water-based gels, such as hydroxy propyl methyl cellulose (HPMC) based gels. In addition to sustained drug release properties of the gel base, HPMC itself has healing properties. The final composition of the gel should have the ability of maintaining its gel form for a suitable time period on the wound, while releasing its phage content. Isolation of selective phages of *Klebsiella pneumoniae* was done from waste water samples. After purification of phage, it has been trapped into HPMC gel. Gels with different concentrations were used to create plaques and their phage release pattern was studied. Finally, it was shown that the 2% HPMC possessed the most appropriate pharmaceutical features, in terms of the release and durability on the site of infection.

Keywords: HPMC hydrogel, *Klebsiella pneumoniae*, Phage therapy, Superficial infections, Sustained release.

1. Introduction

Bacteriophages (phages) are natural particles that can attack bacteria (1). The intrinsic properties of phages made them suitable for the treatment of pathogenic bacteria in human infec-

tions (1-3). The resistance of bacteria to various antibiotics has been accelerated in recent years (4-5). The World Health Organization (WHO) has warned several times for bacterial antibiotic resistance (6). Increasing of antibiotic resistant infections has caused so many problems in modern society. One of the most striking examples of these problems is infected wounds and particularly burn wounds in hospitals (7). Strains such as *Pseudo-*

Corresponding Author: Mohammad Ali Mobasher, Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
Email: mohammadalimobasher@gmail.com

monas aeruginosa, *Klebsiella pneumonia* (*K. pneumonia*), *Escherichia coli*, and *Staphylococcus aureus* can infect burn wounds. In these infections and other superficial local infections, phages can be used selectively for each particular strain (8).

Choosing the best pharmaceutical form in any type of treatment is an important factor in the efficiency of the method (9). The best way to deal with superficial infections is topical application of the drug (7, 9). Among the various methods used to treat superficial infections, one and perhaps the best way is the use of water-based gels, such as hydroxy propyl methyl cellulose (HPMC) (10). In addition to the sustained drug release properties of the gel base (which is an important factor in the phage delivery), HPMC itself has healing properties (11-12). Finally, it can be noted that due to the ability of continuous phage release on the infected wound and the healing properties of the gel, phage delivery by HPMC pharmaceutical dosage form in the superficial infections can be an ideal route.

Two parameters of phage release rate at the wound site and the required time to infect certain number of bacteria in the wound are very important. The final composition of the gel should have the ability of keeping its gel form for suitable time on the wound while releasing its phage content. Phages can achieve higher doses after elimination of bacteria, based on their inherent properties. So, the most important factor in the regulation of the two items, depends on the concentration of the gel.

In this study, we aim to isolate phages and study their release rates from gels composed from different concentrations of HPMC .

2. Materials and methods

2.1. Bacteria and phage preparation

Klebsiella pneumoniae strain ATCC 13883 was purchased from “Scientific and Industrial Research Organization of Iran”.

Waste water samples, as good sources of phages, were collected from Vali Asr hospital of Fasa, Iran. Samples were centrifuged and the sediments were removed. The samples were filtered through 0.45 and 0.22 μm filters in two steps. These filtrates were used as phage sources. About 10 cc of bacteria in the exponential growth phase and 100 μl of filtrate were mixed and inoculated

in 200 cc medium. After 24 hr of incubation in a shaking incubator in 120 rpm (Chest-Type GYRO-MAX 777 Incubator Shaker, Amerex Instruments, Inc.), the whole culture was centrifuged (7000 rpm for 7 minutes). The supernatant was removed and filtered. It was expected that phages were amplified in the supernatant liquid, if any phages existed in the sample in the first stage. So, the liquid was refrigerated and stored for plaque assay and spot assay.

2.2. Plaque assay

Plaque assay was performed by double layer agar method (13). 200 μl of bacteria and 100 μl of phage (in constant ratio at all stages) were mixed in 3 ml of soft agar (0.7% LB agar). The mixture was then poured on 1.5% LB agar plates. After 24 hr of incubation, plates were observed. Plaques should be seen if initial samples had any specific phages for *K. pneumoniae*.

2.3. Spot assay

Bacterial solution was mixed in 3 ml of soft agar and poured on the surface of of 1.5% LB agar plates. After about 30 minutes, 3 small drops of phage solution (amount of each one was about 10 μl) were applied on plate. After 24 hr of incubation, plates were examined. Phage sites should be lysed and look like a large plaque.

2.4. Phage purification

An isolated phage plaque was selected and plucked by a Pasteur pipette (both bottom and top of the agar) and dissolved in 2 cc suspension medium (SM) or saline. After filtration, 100 μl of this liquid was added to 10 cc of bacteria in the exponential growth phase. Following 24 hr of incubation, the culture media was centrifuged and the supernatant was removed and filtered. Plaque assay was performed again. This cycle was repeated for 3 times to achieve a pure phage source.

2.5. HPMC preparation

HPMC powder was dispersed in water and stirred about 2 hr to 12 hr at a temperature of 85 $^{\circ}\text{C}$. Different concentrations of gel were prepared in sterile conditions (2%, 4%, 8% and 16% W/V). Then phage stocks were prepared in two




Figure 1. TEM picture of phage samples that infected *K. pneumoniae* shows the morphology of siphoviridae family.

different concentrations (2×10^2 and 2×10^3 pfu/ml). Each concentration of phage and gel were mixed in equal volume ratios (1:1). Finally, eight pharmaceutical dosage forms (2×10^2 and 2×10^3 pfu/ml of phage in 1, 2, 4 and 8 % gel based carrier) were obtained.

2.6. Phage release pattern test

For evaluation of phage release pattern from HPMC gel, single layer agar method was used. In this method, a plate of 1.5% LB agar was placed in incubator for 12 hr to become dry. Then 100 µl of bacteria as a layer was poured on the plate. After 30 minutes, 2 ml of the prepared gel was distributed on the surface of the plate. The number of created plaques in 24 and 48 hr were counted. To measure the release pattern of phages from HPMC gels through a specific time, after culture of the bacteria on the surface of the plates,

they were incubated for 4 hr for an initial growth. After addition of the bacteriophage containing gel, the results were reported based on the number of plaques after 72 hr of incubation. The method was more like a single layer plaque assay.

2.7. TEM analysis

Ten µl of phage lysate with high titer was placed on carbon grids and stained with 1% uranyl acetate. The used TEM device was CM-10 by Philips.

3. Results

Isolated and purified phages were evaluated and determined using transmission electron microscopy (TEM). TEM analysis of phages from sewage samples that infected *K. pneumoniae*, showed KLPN types that belong to the siphoviridae family (Figure 1).

Table 1. Percent of released phage from HPMC carrier in two concentrations of loaded phages (2×10^2 and 2×10^3 pfu/ml).

Phage concentration (pfu/ml)	Gel concentration (w/v)	Time (hr)	
		24	48
2×10^2	1%	98%	100%
	2%	93%	98%
	4%	82%	84%
	8%	71%	77%
	1%	97%	99%
2×10^3	2%	91%	98%
	4%	79%	81%
	8%	51%	63%




Figure 2. Left: Plaque formation after application of 2 ml phage solution (2×10^3 pfu/ml) directly on the surface of the *K. pneumoniae* agar culture. Right: plaque formation using 2 ml phage solution in 1% HPMC gel (2×10^3 pfu/ml) as a sustained release carrier.

The 1% HPMC gel released the highest level of phage particles after 24 hr in both cases of higher and lower phage titers. This formulation released 98% (2×10^2 pfu/ml) and 97% (2×10^3 pfu/ml) of its loaded phages in 24 hr into the plate. Phage release from 2% HPMC gel was reduced to about 93% (2×10^2 pfu/ml) and 91% (2×10^3 pfu/ml). Moreover, in 4% and 8% gels, the release rate was reduced to 82 and 71% (2×10^2 pfu/ml) and 79 and 51% (2×10^3 pfu/ml), respectively.

During 48 hr, 4% and 8% HPMC gel carriers released about 84% and 77% (2×10^2 pfu/ml) and 81 and 63% (2×10^3 pfu/ml) of their stored phage. Since the ratio between the number of phages and bacteria at the infected site must be in a balance for plaque formation, plaques created with low concentrations of gel carriers were clearer and more abundant (Table 1).

4. Discussion

Increasing bacterial resistance rate through the world has surged an interest to find an alternative approach to counter bacterial infections (14). Phage therapy is a novel and accepted way to cope with infections (14). Some types of skin and soft tissue infections are difficult to treat (15). Using new pharmaceutical formulations such as sustained release hydrogels can be very beneficial in these situations. HPMC hydrogels are able to deliver active compounds, chemicals, and bio-

logic elements across the gel to the skin surface (16). So, it can be a good pharmaceutical form of drug delivery in cases of skin burns, injuries, and infections (16). The release of phage in phage therapy using gels, is one of the most important parameters. After evaluation of phage release patterns in different concentrations of HPMC, 1% and 2% HPMC gels were identified as the most effective forms (Figure 2). As it can be seen, the abundance and plaque shapes are the same in plates of phage solution and 1% HPMC gel (Figure 2).

Carrier viscosity grew with increase of HPMC concentrations in gels, proportionally. So, as an advantage, carrier durability on the scars and infections may be longer. In low viscosities (1 and 2%), HPMC hydrogels quickly release their contents on the plate, which is not very favorable; because enough exposure time is necessary for phages to infect bacteria. Moreover, the continuous release of phages at the site of infection seems necessary. The durability for phage release was more than 24 hr in 4% and 8% HPMC gels, and their surveillance was about 2 days on the applied location, but because of phage trapping in the gel and low rates of phage release, their effects were less desirable on the action site. On the other hand, the ratio of the durability and phage release was desirable in 2% HPMC gel. The gel shelf life was about 12 hr on application site. The drug remained for enough favorable time on the action site and released enough phages for phage therapy. How-

ever, in some studies on burn wounds infected by *K. pneumonia*, the best results have been observed with 3% HPMC gels (17-18).

5. Conclusion

Since the chemical treatment by antibiotics actually is reaching its final deadlock, a critical need to replace them is strongly sensed. Usage of phages for eradication of resistant infections especially in recent years is under development (19). Application of hydrogels like HPMC as a sustained release drug carrier can be very suit-

6. References

1. Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I. Bacteriophages and their implications on future biotechnology: a review. *Virol J.* 2012;9:9.
2. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. *Future microbiol.* 2013;8(6):769-83.
3. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. *Bacteriophage.* 2011;1:111-4.
4. Rai M, Deshmukh S, Ingle A, Gade A. Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. *J Appl Microbiol.* 2012;112:841-52.
5. Golkar Z, Bagasra O, Jamil N. Experimental phage therapy on multiple drug resistant *Pseudomonas aeruginosa* infection in mice. *J Antivir Antiretrovir.* 2013;2013: S10:005.
6. Carlet J, Pulcini C, Piddock L. Antibiotic resistance: a geopolitical issue. *Clin Microbiol Infect.* 2014;20:949-53.
7. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. *Clin Microbiol Rev.* 2006;19:403-34.
8. Rose T, Verbeke G, De Vos D, Merabishvili M, Vaneechoutte M, Lavigne R, et al. Experimental phage therapy of burn wound infection: difficult first steps. *Int J Burns Trauma.* 2014;4:66-73.
9. Thiel K. Old dogma, new tricks--21st Century phage therapy. *Nat Biotechnol.* 2004;22:31-6.
10. Joshi SC. Sol-Gel behavior of hydroxypropyl methylcellulose (HPMC) in ionic media including drug release. *Materials.* 2011;4:1861-905.

HPMC gel concentration relation with phage release pattern

able. In this study, after evaluation of HPMC gels viscosity and their phage release pattern, between different concentrations (1, 2, 4 and 8% w/v), 2% HPMC gel showed the best proportionality between release and lasting properties. In some studies in this field, similar results have been obtained. So, this study can be the first step for development of durable and sustained release hydrogels as a carrier for phage delivery in case of wounds and burns infected by resistant bacterial infections.

Conflict of Interest

None declared.

11. Majumdar M, Nayeem N, Kamath JV, Asad M. Evaluation of *Tectona grandis* leaves for wound healing activity. *Pak J Pharm Sci.* 2007;20:120-4.
12. Kelleher PJ. Methods and compositions for the modulation of cell proliferation and wound healing. *Google Patents;* 2000.
13. Kropinski AM, Mazzocco A, Waddell TE, Lingohr E, Johnson RP. Enumeration of bacteriophages by double agar overlay plaque assay. *Methods Mol Biol.* 2009;501:69-76.
14. Alavidze Z, Aminov R, Betts A, Bardiau M, Bretaudeau L, Caplin J, et al. Silk route to the acceptance and re-implementation of bacteriophage therapy. *Biotechnol J.* 2016;11:595-600.
15. Estrella LA, Quinones J, Henry M, Hannah RM, Pope RK, Hamilton T, et al. Characterization of novel *Staphylococcus aureus* lytic phage and defining their combinatorial virulence using the OmniLog® system. *Bacteriophage.* 2016;6:e1219440.
16. Houston DM, Robins B, Bugert JJ, Denny SP, Heard CM. *In vitro* permeation and biological activity of punicalagin and zinc (II) across skin and mucous membranes prone to Herpes simplex virus infection. *Eur J Pharm Sci.* 2017;96:99-106.
17. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. *Expert Rev Anti Infect Ther.* 2011;9:775-85.
18. Kumari S, Harjai K, Chhibber S. Topical treatment of *Klebsiella pneumoniae* B5055 induced burn wound infection in mice using natural products. *J Infect Dev Ctries.* 2010;4:367-77.

19. Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. *Drug Discov Today*. 2005;10:807-9.